The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics.
about
Through the looking glass, mechanistic insights from enantiomeric human defensinsProtein Defense Systems against the Lantibiotic Nisin: Function of the Immunity Protein NisI and the Resistance Protein NSRPotential Use of Antimicrobial Peptides as Vaginal Spermicides/MicrobicidesBioengineering Lantibiotics for Therapeutic SuccessLipidII: Just Another Brick in the Wall?The First Structure of a Lantibiotic Immunity Protein, SpaI from Bacillus subtilis, Reveals a Novel FoldHigh-resolution crystal structure reveals molecular details of target recognition by bacitracinThe Lantibiotic NAI-107 Binds to Bactoprenol-bound Cell Wall Precursors and Impairs Membrane FunctionsPhosphoinositide-mediated oligomerization of a defensin induces cell lysisType AII lantibiotic bovicin HJ50 with a rare disulfide bond: structure, structure-activity relationships and mode of actionLantibiotic resistance.Distinct mechanisms contribute to immunity in the lantibiotic NAI-107 producer strain Microbispora ATCC PTA-5024Antimicrobial lipopeptide tridecaptin A1 selectively binds to Gram-negative lipid IIAntimicrobial Activity of Cationic Antimicrobial Peptides against Gram-Positives: Current Progress Made in Understanding the Mode of Action and the Response of BacteriaAntimicrobial Peptides Targeting Gram-Positive BacteriaBioengineering of the model lantibiotic nisinTurning defense into offense: defensin mimetics as novel antibiotics targeting lipid IIThe Solution Structure of the Lantibiotic Immunity Protein NisI and Its Interactions with Nisin.Engineering of Bacillus subtilis 168 for increased nisin resistance.Transcriptome analysis of the responses of Staphylococcus aureus to antimicrobial peptides and characterization of the roles of vraDE and vraSR in antimicrobial resistance.Production of the Bsa lantibiotic by community-acquired Staphylococcus aureus strains.In silico analysis highlights the frequency and diversity of type 1 lantibiotic gene clusters in genome sequenced bacteria.Nano-engineering the Antimicrobial Spectrum of Lantibiotics: Activity of Nisin against Gram Negative Bacteria.Artificial lantipeptides from in vitro translations.Enhanced membrane pore formation through high-affinity targeted antimicrobial peptides.Lipid-II forms potential "landing terrain" for lantibiotics in simulated bacterial membrane.In vivo activity of nisin A and nisin V against Listeria monocytogenes in mice.Cloning and analysis of the planosporicin lantibiotic biosynthetic gene cluster of Planomonospora alba.Saturation mutagenesis of lysine 12 leads to the identification of derivatives of nisin A with enhanced antimicrobial activity.Site-directed mutations in the lanthipeptide mutacin 1140.The presence of modifiable residues in the core peptide part of precursor nisin is not crucial for precursor nisin interactions with NisB- and NisCBiosynthesis of the antimicrobial peptide epilancin 15X and its N-terminal lactateLantibiotic immunity: inhibition of nisin mediated pore formation by NisIThe lantibiotic nisin induces lipid II aggregation, causing membrane instability and vesicle budding.Mechanism of inhibition of Bacillus anthracis spore outgrowth by the lantibiotic nisin.The Bacillus subtilis GntR family repressor YtrA responds to cell wall antibioticsThe role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation.Mirror image proteins.The effect of environment on the recognition and binding of vancomycin to native and resistant forms of lipid II.Nisin H Is a New Nisin Variant Produced by the Gut-Derived Strain Streptococcus hyointestinalis DPC6484
P2860
Q24652382-CF0357C9-8D3D-4589-B6CC-6260C5415358Q26752597-A0A70E24-0393-4F43-B365-CC080717645EQ26765450-34BC2226-6BAB-4790-8CB4-3FD9B0AFD805Q26774123-8A9D8853-2C98-4766-B0E4-D05627BA024BQ26775024-60CF9E76-7E91-4B53-9273-7E26555F47D2Q27671593-80542FED-E6AE-42DB-ABA2-96074013CC12Q27679545-46DF6EBB-B2A2-4B61-8F8D-878D810552E6Q27682197-78F8834C-64A5-4A06-8909-6E941A94E207Q27682739-C9529341-8A15-4BA0-A99B-9102208D6B2AQ27690184-EBAF3055-8CA3-4DC0-98C0-C9CD7C9C4A09Q27692563-2833D1DB-1AF8-40AC-AE52-24E80E4EA5C5Q27700284-79BC022D-F31C-4360-87AD-CD010DCD5D32Q27728149-CFA322F1-BBB8-4496-9768-53A297919A83Q28072687-6890A5DC-8334-4A37-8349-DBDDD1E5C5FFQ28077888-5700D9BF-36ED-49AE-B6B7-734E5290A051Q28087616-E0B5016E-9C96-467A-B5F6-9E218496FC62Q28534946-9B590163-4F24-4EB1-970A-FEB2CDF092CEQ30380211-6AA665CF-B00A-4020-90E9-24FE77B558CBQ33502559-8091DDD8-2AEF-4E55-9AAA-05DB99B65C3FQ33502861-5C8458DD-3BCC-47F7-95A4-A3D23E6271ACQ33616955-A2E2347B-2742-4004-96FC-AC9C44BAD1D1Q33759122-817244BB-5A4B-4631-93C7-95A0968E1609Q33849047-83BB4B6B-8A6F-4A0A-8A9B-C2D2A45DB4FBQ33884413-C5FEEA64-BA52-4ED5-B079-06959B99D2E9Q34328258-1B8BC9BC-0B09-46A8-955C-D1AAB07D0056Q34339406-16B8431D-1866-4E57-969C-8B8DC1F41BC7Q34572089-7505A996-1A00-49FA-B241-D35524103560Q34615860-108D3EDA-BE3D-4602-9F60-11571DB55699Q34625915-79109B4D-3577-44C2-8D28-3944DFE2E5D1Q34679435-CD0E5C6B-FFD7-4867-88ED-05E87CCB7EC8Q34990399-2DBD6D7D-32CF-472E-A49A-22B2B94F1583Q35180539-31D4E2B2-D508-4317-ACE0-49345DDC0C01Q35205494-3763FCBB-EC96-4307-9B1D-49AED182F76AQ35222127-DF7AE28D-EB83-483F-91D1-B8F9FDB1B5C4Q35227109-11F1278D-AC53-48A4-9681-ED8141B840FAQ35272543-3D73C3E2-B737-4743-850B-720DDAE85387Q35297286-5C243966-46E9-49AB-863D-D7557A1EA3FDQ35302104-2E872E72-2346-45F5-A199-A3746AC0631CQ35815846-9E08E996-6DB6-43CF-B20E-4D6D6433EC26Q35914129-CCABE352-BA62-4902-874C-3BDF9141A477
P2860
The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The nisin-lipid II complex rev ...... ueprint for novel antibiotics.
@ast
The nisin-lipid II complex rev ...... ueprint for novel antibiotics.
@en
The nisin-lipid II complex rev ...... ueprint for novel antibiotics.
@nl
type
label
The nisin-lipid II complex rev ...... ueprint for novel antibiotics.
@ast
The nisin-lipid II complex rev ...... ueprint for novel antibiotics.
@en
The nisin-lipid II complex rev ...... ueprint for novel antibiotics.
@nl
altLabel
The nisin–lipid II complex rev ...... lueprint for novel antibiotics
@en
prefLabel
The nisin-lipid II complex rev ...... ueprint for novel antibiotics.
@ast
The nisin-lipid II complex rev ...... ueprint for novel antibiotics.
@en
The nisin-lipid II complex rev ...... ueprint for novel antibiotics.
@nl
P2093
P2860
P50
P356
P1476
The nisin-lipid II complex rev ...... ueprint for novel antibiotics.
@en
P2093
Ben de Kruijff
Eugene Tischenko
Mandy A G Lutters
Nico A J van Nuland
Robert Kaptein
P2860
P2888
P304
P356
10.1038/NSMB830
P407
P577
2004-09-12T00:00:00Z